Pharmafile Logo
Pharmafocus logo
Advanced Search

immunotherapy

Showing 15 posts of 78 posts found.

opdivo_1

Bristol-Myers Squibb cancer immunotherapy Opdivo approved in EU

April 13, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Bristol-Myers Squibb, Cancer, EU, NICE, approval, immunotherapy, opdivo

Bristol-Myers Squibb has announced that its potentially life-extending cancer immunotherapy, Opdivo (nivolumab), has been approved by the European Commission to …

News
msd

FDA accepts biologics license application for MSD’s allergy immunotherapy drug

April 13, 2016
Research and Development, Sales and Marketing MSD, Merck, allergy, dust mite, house, immunotherapy, mk-8237

MSD (NYSE: MRK) has announced that the US Food and Drug Administration has accepted for review the biologics license application …

News
Adaptimmune

GSK and Adaptimmune expand R&D collaboration

February 3, 2016
Research and Development Adaptimmune, GSK, T-cell therapy, immunotherapy, liposarcoma, rare cancer, sarcoma

Adaptimmune Therapeutics and GlaxoSmithKline have expanded the terms of their strategic collaboration agreement, to run clinical trials of Adaptimmune’s potential …

News
Keytruda image

BioLineRx to test lead candidate with MSD’s Keytruda in pancreatic cancer

January 13, 2016
Research and Development MSD, immunotherapy, keytruda, pembrolizumab

Israeli biopharma company BioLineRx has announced a collaboration with MSD on a Phase II study investigating its lead oncology candidate, …

News
R&D researcher

More breakthroughs in cancer pose the question: Who pays for them?

December 16, 2015
Research and Development Cancer, drug access, immunotherapy, oncology

The molecular revolution over the last decade has done much to help turn cancer into an illness that can be …

Feature
GSK building

GSK and Merck to study immunotherapy combo in solid tumours

November 3, 2015
Research and Development GSK, Merck, immunooncology, immunotherapy, keytruda, phase I

GSK and Merck will start a Phase I clinical trial in humans to evaluate GSK’s investigational cancer drugs with the …

News
R&D

Sanofi and BioNTech in cancer immunotherapy partnership

November 3, 2015
Manufacturing and Production, Research and Development BioNTech, Cancer, Sanofi, immunotherapy

Sanofi and BioNTech have agreed a new multi-year exclusive collaboration and license agreement, to discover and develop up to five …

News
novartis_pic

Novartis acquires Admune Therapeutics

October 21, 2015
Research and Development Admune Therapeutics, Cancer, Novartis, Palobiofarma, immunotherapy

Novartis is broadening its portfolio of cancer immunotherapies with the acquisition of Admune Therapeutics, and signing licensing agreements with Palobiofarma …

News

FDA grants Opdivo breakthrough status for kidney cancer

September 18, 2015
Research and Development, Sales and Marketing BMS, Breakthrough Therapy Designation, Bristol-Myers Squibb, FDA, Kidney cancer, immuno-oncology, immunotherapy, nivolumab, opdivo, renal cell carcinoma

The FDA has given Bristol-Myers Squibb’s immuno-oncology drug Opdivo Breakthrough Therapy Designation as a kidney cancer treatment. The FDA’s decision …

News
Logos

AstraZeneca and Peregrine in immuno-oncology collaboration

August 24, 2015
Research and Development AstraZeneca, Cancer, MEDI4736, Peregrine, Peregrine Pharmaceuticals, bavituximab, durvalumab, immunoncology, immunotherapy, oncology, tumours

AstraZeneca and Peregrine Pharmaceuticals will collaborate on a clinical trial to test two of the companies’ cancer treatments. The Phase …

News
Opdivo

Bristol-Myers Squibb launches Opdivo in the UK for lung cancer

August 12, 2015
Sales and Marketing BMS, Bristol-Myers Squibb, NSCLC, immunotherapy, lung cancer, non small cell lung cancer, non-small cell lung cancer, opdivo

The immuno-oncology drug Opdivo is available in the UK for people with lung cancer, after Bristol-Myers Squibb launched the drug …

News
R&D

Sanofi, Evotec and Apeiron partner on immuno-oncology

August 10, 2015
Research and Development, Sales and Marketing Apeiron, Cancer, Evotec, Sanofi, immuno-oncology, immunotherapy, tumours

Sanofi is partnering with biotech companies Evotec and Apeiron to develop new cancer immuno-oncology therapies.The companies say the potential new …

News
MedImmune building Cambridge

MedImmune and Mirati to partner on lung cancer combo

August 6, 2015
Research and Development AstraZeneca, Cancer, MedImmune, Mirati, Mirati Therapeutics, NSCLC, durvalumab, immuno-oncology, immunotherapy, lung cancer, mocetinostat

MedImmune is entering into an exclusive clinical trial collaboration with US-based Mirati Therapeutics to test a novel immuno-oncology combination in …

News
Amgen image

Amgen bets on immunotherapy future

June 15, 2015
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, immunotherapy, oncology, oncolytic, tom lillie

When we speak to Tom Lillie he’s brimming with excitement about the future for Amgen in oncology and the future …

Feature
lilly_logo_building

Lilly and AstraZeneca collaborate on cancer trials

May 29, 2015
Research and Development AstraZeneca, Cancer, Eli Lilly, MedImmune, immuno-oncology, immunotherapy, lilly, oncology, phase I

AstraZeneca and Eli Lilly are teaming up to run a clinical trial of two of the companies’ anti-cancer drugs. The …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025